Abstract
The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 63-71 |
| Number of pages | 9 |
| Journal | Current Treatment Options in Neurology |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2007 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Neuro-ophthalmologic manifestations of sarcoidosis. / Stern, Barney; Corbett, James.
In: Current Treatment Options in Neurology, Vol. 9, No. 1, 01.01.2007, p. 63-71.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Neuro-ophthalmologic manifestations of sarcoidosis
AU - Stern, Barney
AU - Corbett, James
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.
AB - The first-line treatment for the neuro-ophthalmologic manifestations of sarcoidosis is corticosteroid therapy. Prednisone, 0.5 to 1 mg/kg/day, is initially prescribed for 2 to 4 weeks, before a slow taper is begun as the patient's symptoms and examination are monitored. Patients frequently require adjunct therapy, which can be in the form of immunomodulatory drugs such as pentoxyfillin, hydroxychloroquine, or thalidomide, or immunosuppressive drugs such as mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide. Individuals with profound visual compromise or progressive disease may benefit from high-dose intravenous methylprednisolone or tumor necrosis factor-α antagonists such as infliximab. Attention to the overall medical status of the patient is essential to ensure that an optimal clinical status is achieved.
UR - http://www.scopus.com/inward/record.url?scp=33847345463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847345463&partnerID=8YFLogxK
U2 - 10.1007/s11940-007-0032-3
DO - 10.1007/s11940-007-0032-3
M3 - Review article
C2 - 17288891
AN - SCOPUS:33847345463
VL - 9
SP - 63
EP - 71
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
SN - 1092-8480
IS - 1
ER -